Elipovimab

Elipovimab is a monoclonal antibody designed for the treatment of Ebola virus disease. It is one of the three antibodies in the Ebola treatment drug Inmazeb.

History

Elipovimab, along with atoltivimab and maftivimab, was developed by Regeneron Pharmaceuticals as part of a triple-antibody cocktail for the treatment of Ebola virus disease. The drug was approved for use in the United States in October 2020.

Mechanism of action

Elipovimab works by binding to the surface glycoprotein of the Ebola virus, preventing the virus from entering human cells. This stops the virus from replicating and spreading throughout the body.

Clinical trials

Elipovimab has been tested in several clinical trials, both as a standalone treatment and as part of the Inmazeb cocktail. These trials have shown that the drug is effective in treating Ebola virus disease, with a significant reduction in mortality compared to other treatments.

Side effects

Common side effects of elipovimab include fever, chills, fatigue, rash, and nausea. In rare cases, the drug can cause severe allergic reactions.

See also

• Monoclonal antibodies
• Ebola virus disease
• Regeneron Pharmaceuticals
• Inmazeb

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia